Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 8:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1345–1368 of 4,097 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Neuromuscular Disorder Clear all
Terminated Not applicable Interventional

Modulating Neuropathic Pain With Transcranial Direct Current Stimulation

NCT04581525
View directory record Official record
Conditions
Pain, Neuropathic, Complex Regional Pain Syndromes, Phantom Limb Pain, Spinal Cord Injuries
Interventions
transcranial direct current stimulation
Device
Lead sponsor
Susan McDowell
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 18, 2026, 8:44 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Antioxidant Therapy in RYR1-Related Congenital Myopathy

NCT02362425
View directory record Official record
Conditions
Neuromuscular Disease
Interventions
N-acetylcysteine, Placebo
Drug
Lead sponsor
National Institute of Nursing Research (NINR)
NIH
Eligibility
7 Years and older
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 24, 2019 · Synced Oct 18, 2026, 8:44 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

AIM's Writing for Healing: A Workshop for Individuals Living With Paralysis

NCT04721717
View directory record Official record
Conditions
Spinal Cord Injuries, Multiple Sclerosis, Transverse Myelitis, Amyotrophic Lateral Sclerosis
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 18, 2026, 8:44 AM EDT
Recruiting Not applicable Interventional

Evaluating Long-term Use of a Pediatric Robotic Exoskeleton (P.REX/Agilik) to Improve Gait in Children With Movement Disorders

NCT05726591
View directory record Official record
Conditions
Cerebral Palsy, Muscular Dystrophy, Spina Bifida, Incomplete Spinal Cord Injury
Interventions
EA-KAFO
Device
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
3 Years to 17 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Oct 18, 2026, 8:44 AM EDT
Completed Not applicable Interventional

Complementary and Alternative Medicine (CAM) for Fibromyalgia

NCT02053090
View directory record Official record
Conditions
Fibromyalgia
Interventions
Group Education and Stretching, Group Acupuncture
Behavioral · Procedure
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
431 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 24, 2015 · Synced Oct 18, 2026, 8:44 AM EDT
No Longer Available No phase listed Expanded access

Treatment Use of 3,4-Diaminopyridine

NCT01765140
View directory record Official record
Conditions
Myasthenic Syndromes, Congenital
Interventions
3,4-diaminopyridine
Drug
Lead sponsor
Vern C. Juel, M.D.
Other
Eligibility
Not listed
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 20, 2025 · Synced Oct 18, 2026, 8:44 AM EDT
Not listed Phase 2 Interventional

Lidorestat (IDD 676) for the Treatment of Diabetic Neuropathy

NCT00043797
View directory record Official record
Conditions
Diabetic Polyneuropathy
Interventions
Lidorestat (IDD 676)
Drug
Lead sponsor
The Institute for Diabetes Discovery, LLC
Industry
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
11
States / cities
Scottsdale, Arizona • Glendale, California • Greenbrae, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 18, 2026, 8:44 AM EDT
Completed Phase 4 Interventional Results available

Lovaza® and Microvascular Function in Type 2 Diabetes

NCT00931879
View directory record Official record
Conditions
Hypertriglyceridemia, Diabetic Neuropathy
Interventions
omega-3-ethyl esters, Placebo
Drug
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
18 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 18, 2026, 8:44 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Retinal Imaging in Neurodegenerative Disease

NCT03233646
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment, Parkinson's Disease, Multiple Sclerosis, Huntington Disease, Lewy Body Dementia, Frontotemporal Dementia, Amyotrophic Lateral Sclerosis (ALS), APOE-4 Positive, Traumatic Brain Injury, Concussion, Post-Traumatic Stress Disorder, Down Syndrome, Neuro-Degenerative Disease, Normal Cognition
Interventions
Retinal and Choroidal Imaging
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 18, 2026, 8:44 AM EDT
Completed Early Phase 1 Interventional

BXQ-350 Pharmacokinetic/Pharmacodynamic Study in Cancer Patients

NCT05291286
View directory record Official record
Conditions
Neuropathy;Peripheral, Chemotherapy-induced Peripheral Neuropathy
Interventions
BXQ-350, Placebo
Drug · Other
Lead sponsor
Bexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
Cincinnati, Ohio • Columbus, Ohio • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Oct 18, 2026, 8:44 AM EDT
Completed Phase 2 Interventional Results available

SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors

NCT01661283
View directory record Official record
Conditions
Malignant Peripheral Nerve Sheath Tumors, MPNST, Sarcoma
Interventions
everolimus, bevacizumab
Drug
Lead sponsor
Sarcoma Alliance for Research through Collaboration
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
12
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2019 · Synced Oct 18, 2026, 8:44 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Generalized Hypersensitivity in Patients With Fibromyalgia Syndrome

NCT04415866
View directory record Official record
Conditions
Fibromyalgia
Interventions
Paced Auditory Serial Addition task (PASAT)
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 21, 2025 · Synced Oct 18, 2026, 8:44 AM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Impact of Orally Administered BPM31510 on Mitochondrial Energetics in Older Adults With Sarcopenia

NCT04999488
View directory record Official record
Conditions
Sarcopenia
Interventions
BPM31510, Placebo
Drug · Other
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
65 Years to 90 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Oct 18, 2026, 8:44 AM EDT
Enrolling by invitation Not applicable Interventional

Impact of Robotic Glove Use on Quality of Life, Grip Strength and Fine Motor Control in ALS

NCT07298486
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
Robotic Glove Use
Device
Lead sponsor
Nova Southeastern University
Other
Eligibility
18 Years to 99 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Davie, Florida
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 18, 2026, 8:44 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Passive Limb Movement Study

NCT05935670
View directory record Official record
Conditions
Stroke, Vascular Diseases, Ischemic
Interventions
Ischemic Conditioning
Device
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 85 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 18, 2026, 8:44 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers

NCT05395624
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS), Parkinson Disease (PD), Alzheimer Disease (AD), Multiple Sclerosis (MS)
Interventions
18F-OP-801
Drug
Lead sponsor
Ashvattha Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
3
States / cities
San Francisco, California • Stanford, California • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 2, 2025 · Synced Oct 18, 2026, 8:44 AM EDT
Available No phase listed Expanded access

Intermediate-size Patient Population Expanded Access Protocol

NCT07088159
View directory record Official record
Conditions
ALS (Amyotrophic Lateral Sclerosis)
Interventions
Tazbentetol
Drug
Lead sponsor
Spinogenix
Industry
Eligibility
18 Years to 85 Years
U.S. locations
16
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 18, 2026, 8:44 AM EDT
Completed Phase 3 Interventional

Comparison of Safety and Efficacy of Tizanidine Hydrochloride Capsules Versus Zanaflex® (Tizanidine Hydrochloride Tablets) Taken While in the Fed State (Just After a Meal) and in the Fasted State (Before a Meal) in Patients With Moderate to Severe Spasticity.

NCT00047580
View directory record Official record
Conditions
Multiple Sclerosis, Muscle Spasticity, Spinal Cord Injury, Stroke
Interventions
tizanidine hydrochloride capsule
Drug
Lead sponsor
Elan Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
16
States / cities
Tucson, Arizona • Encinitas, California • Northridge, California + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Oct 18, 2026, 8:44 AM EDT
Terminated Phase 1 Interventional

Study of ASN003 in Subjects With Advanced Solid Tumors

NCT02961283
View directory record Official record
Conditions
Neoplasms, Melanoma, Colorectal Neoplasm, Carcinoma, Non-small Cell Lung
Interventions
ASN003 ascending doses, ASN003 MTD
Drug
Lead sponsor
Asana BioSciences
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
5
States / cities
Los Angeles, California • Tampa, Florida • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Oct 18, 2026, 8:44 AM EDT
Withdrawn Not applicable Interventional

Oral Thiamine for the Treatment of Painful Diabetic Peripheral Neuropathy

NCT00279266
View directory record Official record
Conditions
Peripheral Neuropathy, Diabetes Mellitus, Diabetes Complications
Interventions
Thiamine
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated May 13, 2015 · Synced Oct 18, 2026, 8:44 AM EDT
Not listed Phase 1 Interventional

Human Spinal Cord Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis

NCT01348451
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
surgical implantation
Device
Lead sponsor
Neuralstem Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 10, 2016 · Synced Oct 18, 2026, 8:44 AM EDT
Terminated Phase 2 Interventional Results available

Phase 2B Extension Study of Ataluren (PTC124) in Duchenne/Becker Muscular Dystrophy (DMD/BMD)

NCT00847379
View directory record Official record
Conditions
Duchenne Muscular Dystrophy, Becker Muscular Dystrophy
Interventions
Ataluren
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
5 Years and older · Male only
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
15
States / cities
Sacramento, California • Aurora, Colorado • Gulf Breeze, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2020 · Synced Oct 18, 2026, 8:44 AM EDT
Recruiting Not applicable Interventional

Efficacy of Red Kinesiology Tape on Carpal Tunnel-Like Symptoms and Performance in Esports Gamers

NCT06757062
View directory record Official record
Conditions
Carpal Tunnel Syndrome
Interventions
Kinesiology Tape
Device
Lead sponsor
University of Nevada, Las Vegas
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jan 3, 2025 · Synced Oct 18, 2026, 8:44 AM EDT
Recruiting No phase listed Observational

Natural History Study for Charcot Marie Tooth Disease

NCT05902351
View directory record Official record
Conditions
Charcot-Marie-Tooth Disease, Charcot-Marie-Tooth, Charcot-Marie-Tooth Disease, Type IA, Charcot-Marie-Tooth Disease Type 2A, Charcot-Marie-Tooth Disease Type 2, Charcot-Marie-Tooth Disease, Type 2C, Charcot-Marie-Tooth Disease Type 2A2B, Charcot-Marie-Tooth Disease Type 2B2, Charcot-Marie-Tooth Disease Type 2A1, Charcot-Marie-Tooth Disease Type 4B1, Charcot-Marie-Tooth Disease, Type IB, Charcot-Marie-Tooth Disease Type 2B1, Charcot-Marie-Tooth Disease Type 2U (Diagnosis), Charcot-Marie-Tooth Disease Type 4A, Charcot-Marie-Tooth Disease, Type 4A, Axonal Form, Charcot-Marie-Tooth Disease Type 2A2A, Charcot-Marie-Tooth Disease Type 2S (Disorder), Charcot-Marie-Tooth Disease and Deafness, Charcot-Marie-Tooth Disease Type 4B2, Charcot-Marie-Tooth Disease Type 4H, Charcot-Marie-Tooth Disease Type 1F, Charcot-Marie-Tooth Disease Type 4C, Charcot-Marie-Tooth Disease Type 4E, Charcot-Marie-Tooth Disease Type 1D, Charcot-Marie-Tooth Disease Type 2Q (Diagnosis), Charcot-Marie-Tooth Disease Type 2A2, Charcot-Marie-Tooth Disease Type 2N (Diagnosis), Charcot-Marie-Tooth Disease Type 2B5, Charcot-Marie-Tooth Disease Type 2D, Charcot-Marie-Tooth Disease Type 4D, Charcot-Marie-Tooth Disease Type 2K, Charcot-Marie-Tooth Disease Type 2L (Diagnosis), Charcot-Marie-Tooth Disease Type 2T, Charcot-Marie-Tooth Disease Type 2I, Charcot-Marie-Tooth Disease Type 2J, Charcot-Marie-Tooth Disease Type 2E, Charcot-Marie-Tooth Disease Type 2G, Charcot-Marie-Tooth Disease Type 1C, Charcot-Marie-Tooth Disease Type 2R, Charcot-Marie-Tooth Disease Type 2O (Diagnosis), Charcot-Marie-Tooth Disease Type 2M, Charcot-Marie-Tooth Disease Type 2P, Charcot-Marie-Tooth Disease Type 2Y, Charcot-Marie-Tooth Disease Type 4F (Diagnosis), Charcot-Marie-Tooth Disease Type 4B3, Charcot-Marie-Tooth Disease Type 2H, HNPP, X-Linked Charcot-Marie-Tooth Disease, Charcot Marie Tooth Disease (CMT)
Interventions
Not listed
Lead sponsor
Hereditary Neuropathy Foundation
Government
Eligibility
Not listed
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 18, 2026, 8:44 AM EDT